StockData
Curanex Pharmaceuticals Inc logo

Curanex Pharmaceuticals Inc (CURX) stock

CURXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$4.70−0.00 (-0.00%)

Close on Nov 18, 2026Market cap $7.37MP/E –Yield –

Curanex Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Curanex Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $9.11M. For fiscal 2025 it was $2.99M.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.99M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$1.95M+188.2%
Q2 FY2026Jun 30, 2026$2.59M–
Q1 FY2026Mar 31, 2026$2.26M–
Q4 FY2025Dec 31, 2025$2.31M–
Q3 FY2025Sep 30, 2025$677.47K–

More Curanex Pharmaceuticals figures

See a number that looks wrong?